Figure 2

Best change from baseline in investigator-assessed measurements of target lesions using RECIST (version 1.0) was determined for patients who had baseline and at least one evaluable postbaseline radiographic scan in the first 12 weeks ( n =64). BRAF mutation status is based on sponsor analyses of archival tumour tissue and investigator reporting. RECIST=Response Evaluation Criteria in Solid Tumours.